Ascendis Pharma A/S $ASND Stock Position Trimmed by New York State Common Retirement Fund

New York State Common Retirement Fund lessened its holdings in shares of Ascendis Pharma A/S (NASDAQ:ASND) by 6.9% in the third quarter, according to its most recent filing with the SEC. The firm owned 169,894 shares of the biotechnology company’s stock after selling 12,664 shares during the quarter. New York State Common Retirement Fund owned about 0.28% of Ascendis Pharma A/S worth $33,777,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. First Horizon Advisors Inc. purchased a new stake in shares of Ascendis Pharma A/S during the second quarter valued at $41,000. Hantz Financial Services Inc. lifted its stake in Ascendis Pharma A/S by 291.1% in the second quarter. Hantz Financial Services Inc. now owns 352 shares of the biotechnology company’s stock valued at $61,000 after acquiring an additional 262 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in shares of Ascendis Pharma A/S by 115.3% during the 3rd quarter. Farther Finance Advisors LLC now owns 478 shares of the biotechnology company’s stock worth $95,000 after acquiring an additional 256 shares in the last quarter. Toth Financial Advisory Corp boosted its holdings in shares of Ascendis Pharma A/S by 33.7% during the 3rd quarter. Toth Financial Advisory Corp now owns 595 shares of the biotechnology company’s stock worth $118,000 after buying an additional 150 shares during the period. Finally, GAMMA Investing LLC increased its stake in shares of Ascendis Pharma A/S by 15.2% in the third quarter. GAMMA Investing LLC now owns 735 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 97 shares during the period.

Wall Street Analyst Weigh In

A number of analysts have weighed in on ASND shares. Raymond James Financial started coverage on shares of Ascendis Pharma A/S in a report on Friday, October 17th. They issued a “strong-buy” rating and a $271.00 price target for the company. Bank of America increased their price objective on Ascendis Pharma A/S from $246.00 to $260.00 and gave the stock a “buy” rating in a research note on Friday. Cantor Fitzgerald reiterated an “overweight” rating on shares of Ascendis Pharma A/S in a research report on Wednesday, November 26th. Royal Bank Of Canada upped their price target on Ascendis Pharma A/S from $245.00 to $250.00 and gave the company an “outperform” rating in a research note on Tuesday, January 20th. Finally, Stifel Nicolaus upped their price objective on Ascendis Pharma A/S from $254.00 to $256.00 and gave the company a “buy” rating in a report on Thursday, December 11th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $270.76.

Ascendis Pharma A/S Trading Up 1.0%

NASDAQ:ASND opened at $226.10 on Friday. The stock has a market capitalization of $14.01 billion, a PE ratio of -50.92, a P/E/G ratio of 1.18 and a beta of 0.46. The firm has a fifty day simple moving average of $212.18 and a 200 day simple moving average of $201.32. Ascendis Pharma A/S has a 1-year low of $118.03 and a 1-year high of $242.00.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, November 13th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.76). The business had revenue of $250.71 million during the quarter, compared to analyst estimates of $246.91 million. On average, equities analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.